Moderna Announces a Vaccine That Is More Than 94.5% Effective Against COVID-19

Last week, there were a series of announcements about vaccines against the coronavirus. Moderna Pharmaceutics announced today that its vaccine is more than 94.5% effective. In addition, it has a significant advantage over its competitor Pfizer.

COVID-19 Vaccine

COVID-19 Vaccine

On November 9, Pfizer announced that its vaccine against Covid-19 was 90% effective, followed by Russia, which declared on November 11 that its vaccine was 92% effective. Today Moderna issued a press release on the efficacy of its candidate vaccine against Covid-19 and declared that it was more than 94.5% effective. Again, this is just a press release, without a published scientific study, so the information may be questionable.

Read Also: Is the Russian COVID-19 Vaccine Really More Effective Than Pfizer’s?

94.5% efficacy in 95 patients with Covid

Moderna reported provisional results of Phase 3 clinical trials, so its vaccine candidate, mRNA-1273, is in approximately the same phase as its direct competitor, Pfizer’s BNT162b2. Both vaccines are based on the same technology, a messenger RNA vaccine, and require two injections.

The mRNA-1273 vaccine has been tested in a total of more than 30,000 people and its efficacy has been tested in 95 patients with Covid-19. Among them were 15 adults over 65 years of age and 20 people from different ethnic backgrounds. Ninety of them received a placebo and five received the vaccine.

Compared to the placebo group, the mRNA-1273 vaccine is more than 94.5% effective in preventing the disease two weeks after the second injection. It is currently the most effective vaccine. Participants reported no serious side effects, but still many inconveniences: Fatigue (9.7%), myalgia (8.9%), arthralgia (5.2%), headaches (4.5%), and pain (4.1%) are the most common.

Read Also: COVID-19: Restaurants, Hotels and Gyms Are the Main Vectors of Virus Transmission

Storage in a regular refrigerator is possible

In a separate press release, Moderna provided information on the storage and stability of its vaccine. Pfizer’s vaccine, which is also based on messenger RNAs, must be stored at -80°C, but the mRNA-1273 vaccine can be stored at 2-8°C for 30 days. It remains stable at room temperature for about 12 hours. After six months it should be stored at -15 to -20°C. This is an undeniable advantage over the Pfizer vaccine since it can be easily stored in a refrigerator before injection.

Modern will submit its vaccine candidate to the Food and Drug Administration (FDA) for emergency approval within a few weeks. The US government has already signed a $1.525 billion vaccine purchase agreement. The pharmaceutical company plans to produce 20 million doses of vaccine for the United States by the end of 2020 and up to 1 billion doses of vaccine worldwide by 2021.

Read Also: Vaccination Risk: The importance of the National Vaccine Injury Compensation Program

References

Moderna’s COVID-19 Vaccine Candidate Meets its Primary Efficacy Endpoint in the First Interim Analysis of the Phase 3 COVE Study

Recommended Reads:

Health News

Coronavirus Pandemic: The Flip-Flops of the Scientific Community

Is There A Link Between Pandemics and Climate Change?

Vaccines May Protect You Against Other Diseases Besides Those They Were Made for According To Study

Too Much Salt Weakens the Immune System According to Study

Genf20 Plus Review: Why Are People Rushing to Buy This HGH Supplement?

COVID-19: All the Essential Vitamins and Minerals for a Strong Immune System

Growth Factor Plus: Benefits, Ingredients, Side effects, Cost and Testimonials

Immune Defence Review: Swiss Research Labs Develops Lozenges to Boost Immune Response

 

Conversation

Want to live your best life?

Get the Gilmore Health Weekly newsletter for health tips, wellness updates and more.